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Plasmacytoid dendritic cells (pDCs) are important mediators of innate immunity that act mainly through secretion of interferon
(IFN)-a. Previous studies have found that these cells can suppress HIV in vitro; additionally, pDCs have been shown to be
severely reduced in the peripheral blood of HIV-infected individuals. In the present study, we sought to determine the ability
of pDCs to directly suppress viral replication ex vivo and to delineate the potential mechanisms whereby pDCs are depleted in
HIV-infected individuals. We demonstrate that activated pDCs strongly suppress HIV replication in autologous CD4
+ T cells via
a mechanism involving IFN-a as well as other antiviral factors. Of note, unstimulated pDCs from infected individuals who
maintain low levels of plasma viremia without antiretroviral therapy were able to suppress HIV ex vivo via a mechanism
requiring cell-to-cell contact. Our data also demonstrate that death of pDCs by both apoptosis and necrosis is induced by
fusion of HIV with pDCs. Taken together, our data suggest that pDCs play an important role in the control of HIV replication
and that high levels of viral replication in vivo are associated with pDC cell death via apoptosis and necrosis. Elucidation of the
mechanism by which pDCs suppress HIV replication in vivo may have clinically relevant implications for future therapeutic
strategies.
Citation: Meyers JH, Justement JS, Hallahan CW, Blair ET, Sun YA, et al (2007) Impact of HIV on Cell Survival and Antiviral Activity of Plasmacytoid
Dendritic Cells. PLoS ONE 2(5): e458. doi:10.1371/journal.pone.0000458
INTRODUCTION
Dendritic cells (DCs) are bone marrow-derived cells vital to the
proper development of an immune response. In humans, at least
two subtypes of dendritic cells exist, myeloid DCs (mDCs) and
plasmacytoid DCs (pDCs). mDCs serve as the classical antigen-
presenting cells important to initiate and maintain an adaptive
immune response, while pDCs are mainly linked to innate
immunity [1]. Upon encountering a pathogen, pDCs produce
large quantities of interferon-alpha (IFN-a), which directly inhibits
viral replication and can also act to stimulate other immune
competent cells [1,2]. pDCs recognize pathogens via pattern
recognition receptors, such as TLR7, which binds to viral ssRNA,
and TLR9, which binds to unmethylated CpG motifs [2,3].
Triggering of these receptors, which are located in endosomes,
results in pDC activation and IFN-a production [4,5]. Although
they are capable of antigen presentation to T cells, the main
functions of pDCs primarily involve type I interferon production
and associated host defense early in infection.
pDCs express CD4, CXCR4, and CCR5 on their surface and
have been shown to be infected by HIV [6,7,8,9,10,11], although
the in vivo extent and pathogenic relevance of this phenomenon
remain unclear. More importantly, during primary HIV infection,
numbers of pDCs and levels of IFN-a production have been
shown to be severely reduced, leading to speculation that HIV
disease progression may result in part from the failure of pDCs to
limit viral replication [12,13,14,15,16,17]. Upon initiation of
effective antiretroviral therapy in HIV-infected individuals, the
levels of pDCs and their associated IFN-a production have been
shown to partially recover, but they rarely reach levels observed
pre-infection [15,16,18,19,20]. It is unclear to date whether this
reduction in pDCs is due to cell death associated with HIV
infection or to migration from the bloodstream to tissue sites [21].
Despite a number of previous studies examining the interaction
between HIV and pDCs in vitro [7,8,9,10,11,22,23,24,25,26,27],
the ability of patient-derived pDCs to inhibit endogenous viral
replication in autologous CD4
+ T cells and the mechanisms
whereby HIV infection results in a decrease in pDCs have not
been fully elucidated. In the present study, we demonstrate the
ability of activated pDCs from HIV-infected individuals to
potently suppress HIV replication in autologous CD4
+ T cells.
Some of these suppressive effects were mediated by IFN-a,a s
demonstrated by the ability of an anti-IFN-aR antibody to
partially block suppression; however, the data also suggested
involvement of additional factors. Interestingly, unstimulated
pDCs from infected individuals who maintained low levels of
HIV plasma viremia without antiretroviral therapy suppressed
viral replication in autologous CD4
+ T cells via cell-to-cell contact.
Consistent with this observation, DNA microarray analysis
indicated that unstimulated pDCs from patients who have
differing abilities to control HIV have distinct gene expression
profiles. Finally, we demonstrated that decreased numbers of
pDCs in the blood of HIV-infected individuals may be due in part
to HIV-mediated cell death, as exposure of pDCs to a cell line
expressing HIV induced substantial levels of apoptosis and
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RESULTS
pDCs in HIV-infected individuals retain HIV-
suppressive functionality
The role that pDCs play in the pathogenesis of HIV is
incompletely understood. pDCs have been proposed to inhibit
HIV replication in vivo, but this activity has not been directly
demonstrated. Hence, we set out to determine whether unstimu-
lated or activated pDCs from HIV-infected individuals could
directly inhibit viral replication in autologous CD4
+ T cells and
whether the degree of this inhibition related to disease status.
We first addressed the relative abilities of pDCs from HIV-
infected vs. uninfected individuals to suppress HIV replication in
vitro. U87 cell lines expressing CD4 and either CCR5 or CXCR4
(U87-R5 or U87-X4, respectively) were infected with the
appropriate R5- or X4-tropic luciferase reporter HIV, and pDCs
that had been purified from either HIV-infected patients or
uninfected controls were added. The level of HIV transcription
was measured by luciferase activity, and the ability of CpG-
stimulated or unstimulated pDCs to suppress HIV replication was
quantified. Unstimulated pDCs could generally suppress HIV to
a modest degree, while pDCs stimulated via TLR9 by CpG
strongly suppressed virus in all instances. Of note, pDCs from
HIV-infected versus uninfected individuals mediated similar levels
of viral suppression (Figure 1). These data indicate that, despite the
relatively low numbers of pDCs in the peripheral blood of HIV-
infected individuals in vivo, the remaining pDCs seem to retain
their antiviral activity.
Direct suppression of endogenous HIV replication
by pDCs from HIV-infected individuals
In order to analyze the capacity of patient-derived pDCs to inhibit
HIV in a more physiologic setting, we conducted HIV p24 release
assays in which pDCs from an HIV-infected individual were co-
cultured with autologous activated CD4
+ T cells. The degree of
HIV replication was measured by HIV p24 ELISA and the level of
IFN-a production by ELISA at days 3, 5, and 7. In the case of
individuals receiving effective antiretroviral therapy (ART), we co-
cultured pDCs from the current aviremic time point with
autologous CD4
+ T cells cryopreserved at a time when these
individuals had detectable plasma viremia.
In the setting of pDC-CD4
+ T cell co-culture, CpG-stimulated
pDCs strongly suppressed endogenous viral production (Figure 2).
This suppression could be partially reversed by blocking the IFN-
a receptor, indicating that some, but not all, of the suppression was
mediated by IFN-a (Figures 2A and 4A). These data suggest that
additional pDC-derived suppressive factors, possibly including
IFN-a related proteins, might also be involved in the suppression
of HIV replication. To further delineate the ability of pDCs from
individuals at different stages of disease to inhibit viral replication,
we divided the study participants into three groups, aviremic
(ART-treated, plasma viremia,50 copies of HIV RNA per ml
plasma), ‘‘low-viremic’’ (ART-naı ¨ve, plasma viremia,12,500
copies/ml, median 7,320, range 1,025–12,028), and ‘‘high-
viremic’’ (ART-naive, plasma viremia.12,500 copies/ml, median
49,689, range 12,904–134,354). The break point of plasma
viremia, 12,500, was chosen based on the median value of all
ART-naı ¨ve infected individuals (12,466 copies/ml). The majority
of individuals classified as low-viremic have not progressed
virologically over the time they have been observed (from 1–
5 years), whereas those classified as high-viremic have have been
unable to control their viral load over time. Of note, although
pDCs that were not stimulated with CpG were generally
inefficient in suppressing HIV replication, unstimulated pDCs
from the ART-naı ¨ve ‘‘low viremic’’ group suppressed HIV to
a significantly greater degree than did those from aviremic or high-
viremic individuals (p=0.03 and p=0.02, respectively, Figure 2B).
CpG-stimulated pDCs from these low-viremic individuals also
tended to suppress HIV to a greater degree than did stimulated
pDCs from the other two patient groups, but the difference in
suppressive capacity did not reach the level of significance
(Figure 2B, right panel). These data suggest that pDCs from
individuals who maintain low levels of plasma viremia have
a greater antiviral capacity than those from individuals with high
levels of plasma viremia. When unstimulated pDCs from un-
infected individuals were cultured with CD4
+ T cells derived from
viremic individuals, their antiviral activities tended to be similar to
those from high-viremic and aviremic individuals (data not
Figure 1. pDC-mediated suppression of HIV infection in vitro. U87 cell lines expressing CD4 and either CXCR4 or CCR5 were infected with
pseudotyped luciferase HIV SF (X4) or HIV JRFL (R5), respectively. Purified pDCs (10
4) from HIV-infected (n=11) or uninfected (n=4) individuals were
cocultured with 2610
4 U87 cells, with or without 1 mg/ml CpG ODN 2216 in triplicate wells. After two days of incubation, cells were lysed and
luciferase activity following addition of substrates was quantified by a luminometer. Error bars indicate the standard error of the mean.
doi:10.1371/journal.pone.0000458.g001
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qualitatively different from pDCs in HIV-uninfected individuals.
In order to measure the soluble factor-mediated antiviral
capacity of pDCs from HIV-infected individuals, we added
supernatants from CpG-stimulated or unstimulated pDCs to
autologous activated CD4
+ T cell cultures. Supernatants from
stimulated pDCs effectively suppressed HIV replication, and
varying proportions of this suppression could be blocked by anti-
Figure 2. pDC-mediated suppression of HIV replication in autologous
CD4
+ T cells. pDCs were purified from HIV-infected individuals and
plated overnight at 5610
4 cells/well with or without 1 mg/ml CpG ODN
2216. For targets, autologous PBMCs were stimulated overnight with
anti-CD3 and IL-2. On day 0, CD4
+ T cells were purified and plated at
1.2610
6 cells/well alone or with 5610
4 stimulated or unstimulated
pDCs, or with 1.2610
5 purified autologous CD8
+ T cells. Neutralizing
antibody against IFN-a receptor was added at 5 mg/ml to some wells.
Culture supernatants were collected at days 3, 5, and 7 and assayed for
HIV p24 by ELISA. All data shown are from day 7. A) A representative
example of data from a viremic patient. CpG ODN 2216 had no effect on
CD4
+ T cells alone, and the degree of viral suppression by activated
pDCs was comparable to that by CD8
+ T cells. B) Effect of pDCs on HIV
replication in autologous CD4
+ T cells. The degree of HIV suppression
by pDCs was expressed as the difference of log HIV p24 production
between the culture containing CD4
+ T cells alone and the co-culture of
CD4
+ T cells and pDCs (Dlog p24=log HIV p24[CD4 cells alone]-log HIV
p24[CD4+pDC]). Data are shown for unstimulated pDCs (left panel) and
CpG-stimulated pDCs (right panel). Horizontal lines represent median
values. n.s., not significant.
doi:10.1371/journal.pone.0000458.g002
Figure 3. Soluble factor-mediated suppression of HIV replication. HIV
p24 assays were set up as in Figure 2, with the exception that pDCs
were cultured at 5610
4 cells/well separately from CD4
+ T cells, and
supernatants from unstimulated or CpG ODN 2216-stimulated pDC
cultures were added to the T cells at days 0, 3, and 5. Data from day 7
are shown. A) A representative example of data from a viremic patient.
B) Effect of soluble factors secreted by pDCs on HIV replication in
autologous CD4
+ T cells, expressed as in Figure 2. Data are shown for
supernatants from unstimulated pDCs (left panel) and CpG-stimulated
pDCs (right panel). Data are expressed as delta log p24 as described
above. n.s., not significant.
doi:10.1371/journal.pone.0000458.g003
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PLoS ONE | www.plosone.org 3 2007 | Issue 5 | e458Figure 4. Interferon-a in pDC-mediated HIV suppression. A) Effect of neutralizing IFN-a receptor antibody on HIV suppression. The percent of the
HIV suppression observed in co-culture experiments (left panel, data from Figure 2B) or pDC supernatant transfer experiments (right panel, data from
Figure 3B) that could be neutralized by an antibody to the IFN-a receptor is indicated. No significant differences were observed between the degree
of blockade of suppression between patient groups. B) Quantification of IFN-a production in pDC cultures. Culture supernatants from day 3 cultures
of CD4
+ T cells plus: activated pDCs (left panel of each plot, described in Figure 2) or supernatants of activated pDCs (right panel of each plot,
described in Figure 3) were analyzed for IFN-a production by ELISA. Significantly more IFN-a was present in culture supernatants from CD4
+ T cell-
pDC co-culture experiments than in those from cultures containing pDC supernatants (p values indicated for each patient group).
doi:10.1371/journal.pone.0000458.g004
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experiments, soluble factors produced by activated pDCs from
low-viremic individuals suppressed HIV to a greater extent than
did those from high-viremic individuals (Figure 3B; p=0.05).
However, no significant inhibition of HIV replication was
observed with supernatants from any group of unstimulated pDCs
(Figure 3B), suggesting that the suppression depicted in Figure 2B
by unactivated pDCs was exerted mainly through a cell-mediated
mechanism unlikely to be mediated solely by IFN-a. These data
suggest that pDCs from low-viremic infected individuals may
control HIV replication through a previously unexplored mech-
anism.
When the levels of IFN-a in culture supernatants were
measured, CpG-stimulated pDCs co-cultured with autologous
CD4
+ T cells from all three groups of HIV-infected individuals
were found to produce modest to high levels of this cytokine
(Figure 4B). This observation was consistent with the ability of all
of these cells to suppress HIV, which could be partially blocked by
anti-IFN-aR. Although co-cultures containing activated pDCs
from low-viremic individuals appeared to produce more IFN-
a than those containing pDCs from the other two patient groups
(Figure 4B), this apparent difference was not statistically
significant. The neutralizing anti-IFN-aR antibody blocked HIV
suppression to a widely variable and not significantly different
degree in all three patient groups (Figure 4A), in agreement with
their comparable levels of IFN-a production. No detectable IFN-
a was produced by CD4
+ T cells alone, indicating that pDCs were
the sole source of the cytokine (data not shown). Interestingly,
significantly higher levels of IFN-a were produced by activated
pDCs co-cultured with CD4
+ T cells than by activated pDCs
cultured alone in the supernatant transfer experiments in all three
patient groups (p#0.02 in all cases, Figure 4B), suggesting that
CD4
+ T cell-pDC contact enhanced IFN-a production. However,
there were no significant differences in IFN-a production between
cultures containing unstimulated pDCs from individuals with
different levels of HIV viremia (data not shown), which in most
cases was below the assay’s limit of detection. These data support
the idea that the HIV suppression mediated by unstimulated pDCs
from individuals maintaining a low viral load cannot be explained
by IFN-a activity, and that an important cell contact-mediated
interaction occurs between pDCs and CD4
+ T cells.
pDCs from individuals maintaining differing levels
of viremia show distinct gene expression profiles
To address whether pDCs from low-viremic individuals had
a transcriptional profile distinct from that of pDCs from high-
viremic individuals, we conducted DNA microarray analysis of
fresh ex vivo pDCs. Examination of microarray data revealed that
the pDCs isolated from these two groups of HIV-infected
individuals clearly demonstrated distinct patterns of gene expres-
sion (Figure 5). Upon comparing the genes that were significantly
more highly expressed in pDCs from low-viremic individuals
versus those in pDCs from high-viremic individuals (p,0.05), we
found that a large number of these genes were uncharacterized
(data not shown), suggesting that the mechanism by which pDCs
from low-viremic individuals suppress HIV may be mediated
through genes that have been previously undescribed. Although
the differences in gene expression between these two groups of
pDCs were generally subtle, genes upregulated in pDCs from low-
viremic individuals included those encoding adhesion molecules,
molecules involved in apoptotic pathways, and several molecules
that have been previously implicated in HIV suppression,
including LIF and the IL-27 receptor (Figure 5) [28,29]. The
identification of a distinct gene expression profile in pDCs from
low-viremic individuals versus pDCs from high-viremic individuals
supports the idea that these cells may behave differently during
HIV pathogenesis, particularly in their ability to suppress HIV
replication.
HIV can directly kill pDCs
Our data thus far demonstrate that pDCs from HIV-infected
individuals can suppress HIV replication; however, pDC numbers
in peripheral blood are known to be decreased in HIV-positive
compared to HIV-negative individuals, indicating that a loss of
these cells may interfere with their ability to successfully suppress
HIV in vivo. It has been unclear whether this reduction in pDCs is
due to cell death or redistribution of pDCs into various tissue sites
[21]. In order to address this issue in the context of pDC failure to
contain in vivo HIV replication, we sought to determine whether
HIV is involved in the direct killing of pDCs. First, we measured
the levels of pDCs present in blood from HIV-infected and healthy
volunteers by flow cytometry to confirm the reduction in cell
numbers predicted by previous studies [21]. As shown in
Figure 6A, HIV-infected individuals had significantly lower
numbers of pDCs in peripheral blood than did HIV-negative
individuals (p,0.001). We next analyzed whether pDCs were
susceptible to apoptosis assessed by Annexin V and 7-AAD
staining and found that pDCs from both infected and uninfected
individuals underwent apoptosis when triggered via Fas/Fas-L
(data not shown). However, pDCs from low-viremic individuals
were significantly less susceptible to Fas-mediated apoptosis than
were those from aviremic individuals (p=0.02, Figure 6B). It could
thus be postulated that pDCs from low-viremic individuals might
be relatively resistant to Fas-mediated cell death in vivo.
In order to investigate whether decreased levels of pDCs in
HIV-infected individuals could result from accelerated cell death
in the setting of HIV infection, we incubated PBMCs with either
recombinant HIV envelope protein gp160 (Protein Sciences) or
with a CEM cell line chronically infected with HIV (CEM-IIIB)
and assessed resultant pDC viability. Although no significant cell
death was induced by HIV Env (data not shown), CEM-IIIB
induced profound pDC death, as measured by 7-AAD and
Annexin V staining (Figure 6C). Cells staining with Annexin V
alone were considered apoptotic, whereas those that were stained
with both Annexin V and 7-AAD were considered necrotic. The
cell death, both apoptosis and necrosis, was effectively blocked by
addition of the HIV fusion inhibitor T-20 (Figure 6D–E),
suggesting that pDCs are killed by a mechanism involving HIV-
pDC fusion. Uninfected CEM cells did not induce appreciable
pDC death in this system (Figure 6E, left panel). These data
suggest that the reduction in pDC numbers observed in HIV-
infected individuals could be due at least in part to cell death
induced by fusion of pDCs with HIV-infected cells.
DISCUSSION
HIV infection is associated with numerous immunologic deficien-
cies in nearly every type of immune competent cell, including
those that are programmed to inhibit HIV replication [30,31,32].
A more complete understanding of the mechanisms by which HIV
disrupts the antiviral properties of immune system cells could lead
to new approaches to treatment and containment of HIV
replication. pDCs are known to play an important role in innate
immunity against viral infections by secreting IFN-a. Previous
studies have demonstrated that the levels of pDCs in the
peripheral blood are severely compromised in HIV-infected
individuals, but the cause of this depletion, as well as the potential
Plasmacytoid DCs Suppress HIV
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CD4
+ T cells, remain unclear. In the present study, we have
examined the abilities of pDCs from HIV-infected individuals to
suppress HIV replication in autologous CD4
+ T cells. Our data
demonstrated that pDCs from infected individuals who were able
to maintain a low viral load without antiretroviral therapy
manifested considerable HIV-suppressive activity. As we did not
observe similar antiviral activities by unstimulated pDCs from
HIV-negative, aviremic, or high-viremic individuals, it is possible
that pDCs require optimal stimulation in vivo by a low level of virus
to develop potent suppressive activity, or that individuals able to
control viremia have innately distinct pDCs. In support of this
possible requirement for low-level stimulation by virus, previous
studies have shown that HIV can induce activation and
maturation of pDCs [24,26,27]. Activated pDCs from all patient
groups studied could strongly suppress HIV via a mechanism at
Figure 5. Clustering of differentially expressed genes in unstimulated pDCs from HIV-infected individuals with low versus high viral loads. cRNA
was prepared from up to 10
6 pDCs purified from 4 individuals maintaining plasma viremia,12,500 copies/mL and 5 individuals with uncontrolled
viremia.12,500 copies/ml. Transcriptional profiles were assessed using Applied Biosystems high-density genome survey microarrays. Overall, 596
probes were found to be differentially expressed with p,0.05, of which examples are listed at right. Variations in relative levels of gene expression (Z-
score, scale shown below heatmap) are indicated in color, where red regions indicate upregulation, and green regions indicate downregulation. The
hierarchical clustering heatmap was generated using Euclidean distance as the distance measurement between clusters. All genes differentially
expressed with p,0.05 are shown in supplemental Table S1.
doi:10.1371/journal.pone.0000458.g005
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PLoS ONE | www.plosone.org 6 2007 | Issue 5 | e458Figure 6. pDC killing in HIV-infected individuals. A) Plasmacytoid dendritic cell numbers are reduced in HIV-infected versus uninfected individuals.
PBMCs were stained with anti-BDCA-2 (FITC) and anti-CD123 (PE) to measure the levels of pDCs. Horizontal lines represent median values. B) pDCs are
susceptible to Fas-mediated apoptosis. Fas was crosslinked on the surface of PBMCs, and resultant pDC apoptosis was measured by Annexin V
staining. n.s., not significant. C–E) pDC cell death induced by HIV-infected cells. 2610
6 CEM cells chronically infected with HIV (CEM-IIIB) were
incubated for 8 h with 10
7 PBMCs from HIV-infected donors. The levels of apoptosis and necrosis were assessed by Annexin V and 7-AAD staining.
Cells within the pDC (BDCA-2
+/CD123
+) population that were double-positive for both Annexin V and 7-AAD were considered necrotic, while those
positive for Annexin V and negative for 7-AAD were considered apoptotic. In some cultures, 100 mg/ml T20 was added. C) Cells expressing HIV induce
pDC death. The percent of pDCs that were necrotic (Annexin V
+/7-AAD
+) is indicated on the y-axis. PBMCs alone versus PBMCs+CEM-IIIB are shown.
As indicated, CEM-IIIB cells showed a significant induction of cell death vs. cells alone. D) Representative examples of T20-mediated blockade of CEM-
IIIB-induced pDC cell death. E) Cell death is blocked by T20. Cells were incubated with CEM cells alone (left panel), CEM-IIIB, or CEM-IIIB+T20, and the
percentage of pDCs in the apoptotic or necrotic quadrants was quantified. No cell death above baseline was induced by CEM cells alone. Both types
of cell death induced by CEM-IIB cells were significantly reduced (p values indicated) in the presence of T20.
doi:10.1371/journal.pone.0000458.g006
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addition, we demonstrated that HIV can be directly involved in
the killing of pDCs and thus prevent its own suppression,
suggesting that the depletion of pDCs in the peripheral blood
could be in part due to HIV-mediated cell death rather than
migration to tissue sites.
Previous in vitro studies have demonstrated that pDCs can
suppress HIV replication in various cell line systems [25,27];
however, our data provide a physiologic context for these prior
observations by directly addressing the abilities of pDCs from
HIV-infected individuals to suppress endogenous viral replication.
The enhanced HIV-suppressive activities of pDCs from therapy-
naı ¨ve infected individuals who maintain a low level of plasma
viremia suggest that pDCs may play a role in the ability of these
individuals to control HIV replication. A further understanding of
the mechanisms by which these pDCs may suppress HIV
replication in vivo, could provide novel targets and approaches
for future therapeutic strategies.
Whereas previous in vitro work on pDCs obtained from HIV-
infected individuals proposed that IFN-a was the major mecha-
nism of viral inhibition [21,33], our data suggest that pDCs can
also suppress HIV via other mechanisms, involving both cell-to-
cell contact and soluble factors. Signaling initiated by IFN-a can
induce a number of genes [34], many of whose products are to
date uncharacterized; therefore, it is possible that the cell contact-
mediated mechanism involves an IFN-a stimulated transmem-
brane protein. However, DNA microarray analysis revealed that
several IFN-stimulated genes were downregulated in pDCs from
low-viremic individuals (Figure 5), which suggests that the cell-to-
cell contact-mediated mechanism is likely to involve either a novel
IFN-stimulated molecule or a mechanism not mediated by IFN-a.
In support of this observation, a previous study demonstrated that
HIV infection caused the upregulation of a number of IFN-
stimulated genes whose expression did not correlate with control of
HIV replication, leading the authors to conclude that some IFN-a-
induced genes were ineffective in viral suppression [30]. Our
microarray analysis also identified a distinct gene expression
profile in pDCs from low-viremic individuals versus pDCs from
high-viremic individuals, supporting the idea that pDCs from
individuals with differing disease status may behave differently,
both in terms of effector functions and survival. Future analysis of
these gene expression profiles will be useful to delineate the
mechanism of the pDC-CD4
+ T cell contact-mediated suppression
of HIV. pDC-CD4
+ T cell contact, in addition to mediating HIV
suppression in low-viremic individuals, also appeared to increase
the amount of IFN-a produced by stimulated pDCs from all three
groups of HIV-infected individuals. Elucidation of the mechanism
by which cellular contacts between pDCs and CD4
+ T cells
enhance antiviral activities of pDCs awaits future analysis.
Finally, a decrease in peripheral blood pDCs has been shown to
be associated with HIV infection, and previous studies have
indicated that HIV-mediated pDC activation leads to the
upregulation of CCR7 and the production of CCL2, CCL3, and
CCL4 [23,24,26], which may lead to migration of pDCs to various
tissue compartments. However, our data suggest that HIV-
infected cells may also directly fuse with and kill pDCs, which
could account for much of the depletion observed in infected
individuals. . It has been demonstrated that HIV-mediated
activation of pDCs involves endocytosis and not membrane fusion
[22], so it is possible that HIV kills pDCs by a mechanism
independent of that which induces their activation. These
observations may have clinically relevant implications, as strategies
to prevent HIV-mediated pDC death using an agent that blocks
virus-cell fusion could preserve these cells and as a result enhance
the innate ability of the host to suppress HIV replication.
MATERIALS AND METHODS
Study subjects
45 HIV-infected individuals were studied for p24 assays (Figures 2–
4, median viral load 9,189 copies/ml of plasma, range,50–
134,354 copies/ml; median CD4
+ T cell count per mm
3 blood
550, range 251–1,117; Table 1). Several additional HIV-infected
individuals (1 aviremic and 5 viremic) were included in the
apoptosis and microarray assays. Within the limits of our period of
observation, those patients classified as ‘‘low-viremic’’ generally
did not progress virologically, whereas those classified as ‘‘high-
viremic’’ were generally unable to control their plasma viremia.
Leukapheresis was conducted in accordance with protocols
approved by the Institutional Review Boards of the National
Institute of Allergy and Infectious Diseases, National Institutes of
Health and the University of Toronto, Ontario, Canada.
Cell Culture Media
All cells were cultured in RPMI 1640 (Invitrogen) supplemented
with 10% FCS, Penicillin/Streptomycin, and HEPES (all from
Invitrogen).
Purification of pDCs
PBMCs were isolated from leukaphereses by Ficoll-Hypaque (MP
Biomedicals) density gradient centrifugation. Cells (0.8–2610
9)
were resuspended in MACS buffer (PBS, 2 mM EDTA, 0.5%
BSA) and incubated for 10 min. at 4uC with 50 ml FcR blocking
reagent (Miltenyi) per 10
8 cells. Anti-BDCA-4 beads (Miltenyi)
were then added at 50 ml per 10
8 cells followed by incubation for
15 min. at 4uC. Cells were then washed, resuspended at 2610
8
cells/ml, and run over an LS column following the manufacturer’s
protocol (Miltenyi). The eluted positively selected cells were spun
down and run over an MS column following the manufacturer’s
protocol (Miltenyi). Cells eluted from the MS column were
incubated 10 min. at 4uC with 10–20 ml anti-CD14 Dynabeads
(Invitrogen) to deplete residual monocytes, which were removed
via magnetic separation. The remaining enriched pDCs (,90%
pure) were then enumerated and plated at 5610
4 cells/well in
round-bottom 96-well plates with or without stimulation with
1 mg/ml CpG (ODN 2216 [35], Operon). Antibodies used to
Table 1. Patient Characteristics
..................................................................................................................................................
Group n= Median Plasma Viremia
A (copies/ml); [Range] Median CD4 count (cells/mm
3); [Range] Antiretroviral treatment
Aviremic 11 ,50; [N/A] 577; [229–1,117] Yes
Viremia,12,500 17 7,320; [1,025–12,028] 536; [251–815] No
Viremia.12,500 17 49,689; [12,904–134,354] 520; [270–960] No
AMeasured by ultrasensitive bDNA or RT-PCR assay with a detection limit of 50 copies per ml of plasma.
doi:10.1371/journal.pone.0000458.t001
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Miltenyi) and CD123-PE (clone 9F5, BD Biosciences).
Luciferase HIV assays
U87 cells stably transfected with CD4 and either CCR5 or
CXCR4 [36] were seeded in 50 mla t2 610
4 cells/well in 96-well
flat-bottom plates. Cells were infected with 10 ml of luciferase HIV
of the appropriate tropism (JRFL-luc [titer 1120 ng/ml] or SF33-
luc [titer 900 ng/ml], respectively). The plasmids were originally
obtained through the AIDS Reference and Reagent Program,
Division of AIDS, NIAID, NIH, and JRFL-env was originally
from Nathaniel Landau[37]. 1610
4 unstimulated or CpG-
stimulated pDCs from either HIV-infected or –uninfected
individuals were added in 50 ml to some wells. All conditions
were performed in triplicate. Plates were incubated for 48 h at
37uC, after which the cells were lysed by addition of Cell Culture
Lysis Reagent (Promega), frozen at 280uC, and read using the
Promega Luciferase Assay detection system in a luminometer (Bio
Rad Laboratories).
HIV p24 assays
2–4610
8 total PBMCs from HIV-infected individuals were
stimulated overnight with anti-CD3 antibody and rIL-2 (Roche).
CD4
+ and CD8
+ T cells were then purified by negative selection
using a column-based separation technique (StemCell Technolo-
gies) as previously described [38]. 1.2610
6 CD4
+ T cells/mL were
plated in 48-well plates on day 0, and 5610
4 pDCs (purified and
plated as described above, then incubated overnight) with or
without 1 mg/ml CpG ODN 2216 and 5 mg/ml anti-IFN-aR
(Calbiochem) were added to appropriate wells. Additionally,
200 ml supernatant from pDC cultures was added to the CD4
+
T cells in some experiments. 0.5 ml culture supernatant was
collected on days 3, 5, and 7, and levels of HIV p24 and IFN-
a were measured by ELISA (Beckman Coulter and PBL,
respectively). All conditions were set up in single wells, and ELISA
measurements were performed in duplicate. The difference in log
p24 values was used as the measure of suppression.
Microarray Analysis
RNA was prepared from up to 10
6 pDCs using an RNeasy Micro
Kit (Qiagen). 300 ng RNA was used to synthesize cRNA using
a NanoAmp
TM RT-IVT Labeling Kit (Applied Biosystems)
followed by hybridization to Human Genome v2.0 Microarrays
(Applied Biosystems) per manufacturer’s protocols. DNA micro-
arrays were washed as described and read using an Applied
Biosystems 1700 Chemiluminescent Microarray Analyzer. Data
normalization was then performed using quantile normalization
[39]. Statistical analysis was performed using two-sample t test
after filtering out probes not expressed in both conditions. A probe
with signal-noise ratio (S/N) below 3 was considered not expressed
for each sample, and a probe was considered not expressed for
each condition if the probe was not expressed in more than half
the samples in that condition. The hierarchical clustering heatmap
was produced using open-source R language (www.r-project.org)
with Euclidean distance as distance measurement between
clusters. The genes are arranged according to their Pearson
correlation coefficient.
Apoptosis Assays
PBMCs (10
7/well) were incubated for 8 h in 24-well plates with
the following reagents: 1) 2 mg/ml FLAG-tagged FasL crosslinked
with 6 mg/ml of an anti-FLAG tag antibody, 2) 6 mg/ml anti-
FLAG antibody alone, 3) 1.7 mg/ml trimeric gp160 HIV envelope
protein (Protein Sciences), 4) 2610
6 CEM-IIIB cells [40], 5) 2610
6
CEM-IIIB cells plus 100 mg/ml T20 (Roche), 6) 2610
6 uninfected
CEM cells (controls were performed using unrelated patient
samples), or 7) media alone. After incubation, cells were collected
and stained first with anti-BDCA-2-APC (Miltenyi) and anti-
CD123-PE (BD Biosciences) followed by Annexin V-FITC (BD
Biosciences) and 7-AAD (eBioscience). Samples were analyzed by
FACSCanto (BD Biosicences).
Statistical Analysis
Comparison of independent samples was done by the Kruskal-
Wallis test with the Wilcoxon two-sample test. The Wilcoxon
signed rank test was used to determine significance of paired data,
and the adjustment of p values for multiple testing was done by the
Bonferroni method.
SUPPORTING INFORMATION
Table S1 Microarray data. This spreadsheet lists all genes
differentially expressed with a p-value,0.05 between pDCs from
low- versus high-viremic individuals.
Found at: doi:10.1371/journal.pone.0000458.s001 (0.14 MB
CSV)
ACKNOWLEDGMENTS
We thank the patients for their participation in this study. We also thank
Roberta Halpenny and the staffs of the Maple Leaf Clinic and the National
Institute of Allergy and Infectious Diseases HIV Clinic for their invaluable
assistance in the execution of this study.
Author Contributions
Conceived and designed the experiments: TC JM AF. Performed the
experiments: TC JM JJ. Analyzed the data: TC JM JJ CH EB YS.
Contributed reagents/materials/analysis tools: TC SM MO GR SK CK.
Wrote the paper: TC JM AF.
REFERENCES
1. McKenna K, Beignon AS, Bhardwaj N (2005) Plasmacytoid dendritic cells:
linking innate and adaptive immunity. J Virol 79: 17–27.
2. Colonna M, Trinchieri G, Liu YJ (2004) Plasmacytoid dendritic cells in
immunity. Nat Immunol 5: 1219–1226.
3. Rothenfusser S, Tuma E, Endres S, Hartmann G (2002) Plasmacytoid dendritic
cells: the key to CpG. Hum Immunol 63: 1111–1119.
4. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, et al. (2002)
Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at
distinct cellular compartments. Eur J Immunol 32: 1958–1968.
5. Takeda K, Kaisho T, Akira S (2003) Toll-like receptors. Annu Rev Immunol 21:
335–376.
6. Donaghy H, Gazzard B, Gotch F, Patterson S (2003) Dysfunction and infection
of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients
infected with HIV-1. Blood 101: 4505–4511.
7. Fong L, Mengozzi M, Abbey NW, Herndier BG, Engleman EG (2002)
Productive infection of plasmacytoid dendritic cells with human immuno-
deficiency virus type 1 is triggered by CD40 ligation. J Virol 76: 11033–
11041.
8. Patterson S, Rae A, Hockey N, Gilmour J, Gotch F (2001) Plasmacytoid
dendritic cells are highly susceptible to human immunodeficiency virus type 1
infection and release infectious virus. J Virol 75: 6710–6713.
9. Schmitt N, Nugeyre MT, Scott-Algara D, Cumont MC, Barre-Sinoussi F, et al.
(2006) Differential susceptibility of human thymic dendritic cell subsets to X4
and R5 HIV-1 infection. Aids 20: 533–542.
10. Smed-Sorensen A, Lore K, Vasudevan J, Louder MK, Andersson J,
et al. (2005) Differential susceptibility to human immunodeficiency virus
type 1 infection of myeloid and plasmacytoid dendritic cells. J Virol 79:
8861–8869.
Plasmacytoid DCs Suppress HIV
PLoS ONE | www.plosone.org 9 2007 | Issue 5 | e45811. Schmidt B, Scott I, Whitmore RG, Foster H, Fujimura S, et al. (2004) Low-level
HIV infection of plasmacytoid dendritic cells: onset of cytopathic effects and cell
death after PDC maturation. Virology 329: 280–288.
12. Barron MA, Blyveis N, Palmer BE, MaWhinney S, Wilson CC (2003) Influence
of plasma viremia on defects in number and immunophenotype of blood
dendritic cell subsets in human immunodeficiency virus 1-infected individuals.
J Infect Dis 187: 26–37.
13. Donaghy H, Pozniak A, Gazzard B, Qazi N, Gilmour J, et al. (2001) Loss of
blood CD11c(+) myeloid and CD11c(2) plasmacytoid dendritic cells in patients
with HIV-1 infection correlates with HIV-1 RNA virus load. Blood 98:
2574–2576.
14. Feldman S, Stein D, Amrute S, Denny T, Garcia Z, et al. (2001) Decreased
interferon-alpha production in HIV-infected patients correlates with numerical
and functional deficiencies in circulating type 2 dendritic cell precursors. Clin
Immunol 101: 201–210.
15. Kamga I, Kahi S, Develioglu L, Lichtner M, Maranon C, et al. (2005) Type I
interferon production is profoundly and transiently impaired in primary HIV-1
infection. J Infect Dis 192: 303–310.
16. Killian MS, Fujimura SH, Hecht FM, Levy JA (2006) Similar changes in
plasmacytoid dendritic cell and CD4 T-cell counts during primary HIV-1
infection and treatment. Aids 20: 1247–1252.
17. Soumelis V, Scott I, Gheyas F, Bouhour D, Cozon G, et al. (2001) Depletion of
circulating natural type 1 interferon-producing cells in HIV-infected AIDS
patients. Blood 98: 906–912.
18. Almeida M, Cordero M, Almeida J, Orfao A (2006) Persistent abnormalities in
peripheral blood dendritic cells and monocytes from HIV-1-positive patients
after 1 year of antiretroviral therapy. J Acquir Immune Defic Syndr 41:
405–415.
19. Chehimi J, Campbell DE, Azzoni L, Bacheller D, Papasavvas E, et al. (2002)
Persistent decreases in blood plasmacytoid dendritic cell number and function
despite effective highly active antiretroviral therapy and increased blood myeloid
dendritic cells in HIV-infected individuals. J Immunol 168: 4796–4801.
20. Finke JS, Shodell M, Shah K, Siegal FP, Steinman RM (2004) Dendritic cell
numbers in the blood of HIV-1 infected patients before and after changes in
antiretroviral therapy. J Clin Immunol 24: 647–652.
21. Muller-Trutwin M, Hosmalin A (2005) Role for plasmacytoid dendritic cells in
anti-HIV innate immunity. Immunol Cell Biol 83: 578–583.
22. Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, et al. (2005)
Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like
receptor-viral RNA interactions. J Clin Invest 115: 3265–3275.
23. Del Corno M, Gauzzi MC, Penna G, Belardelli F, Adorini L, et al. (2005)
Human immunodeficiency virus type 1 gp120 and other activation stimuli are
highly effective in triggering alpha interferon and CC chemokine production in
circulating plasmacytoid but not myeloid dendritic cells. J Virol 79:
12597–12601.
24. Fonteneau JF, Larsson M, Beignon AS, McKenna K, Dasilva I, et al. (2004)
Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells
and concomitantly induces the bystander maturation of myeloid dendritic cells.
J Virol 78: 5223–5232.
25. Groot F, van Capel TM, Kapsenberg ML, Berkhout B, de Jong EC (2006)
Opposing roles of blood myeloid and plasmacytoid dendritic cells in HIV-1
infection of T cells: transmission facilitation versus replication inhibition. Blood
108: 1957–1964.
26. Schmidt B, Ashlock BM, Foster H, Fujimura SH, Levy JA (2005) HIV-infected
cells are major inducers of plasmacytoid dendritic cell interferon production,
maturation, and migration. Virology 343: 256–266.
27. Yonezawa A, Morita R, Takaori-Kondo A, Kadowaki N, Kitawaki T, et al.
(2003) Natural alpha interferon-producing cells respond to human immunode-
ficiency virus type 1 with alpha interferon production and maturation into
dendritic cells. J Virol 77: 3777–3784.
28. Fakruddin JM, Lempicki RA, Gorelick RJ, Yang J, Adelsberger JW, et al. (2006)
Non-infectious papilloma virus-like particles inhibit HIV-1 replication: implica-
tions for immune control of HIV-1 infection by IL-27. Blood.
29. Patterson BK, Tjernlund A, Andersson J (2002) Endogenous inhibitors of HIV:
potent anti-HIV activity of leukemia inhibitory factor. Curr Mol Med 2:
713–722.
30. Bosinger SE, Hosiawa KA, Cameron MJ, Persad D, Ran L, et al. (2004) Gene
expression profiling of host response in models of acute HIV infection.
J Immunol 173: 6858–6863.
31. Fauci AS, Mavilio D, Kottilil S (2005) NK cells in HIV infection: paradigm for
protection or targets for ambush. Nat Rev Immunol 5: 835–843.
32. Letvin NL, Walker BD (2003) Immunopathogenesis and immunotherapy in
AIDS virus infections. Nat Med 9: 861–866.
33. Gurney KB, Colantonio AD, Blom B, Spits H, Uittenbogaart CH (2004)
Endogenous IFN-alpha production by plasmacytoid dendritic cells exerts an
antiviral effect on thymic HIV-1 infection. J Immunol 173: 7269–7276.
34. Der SD, Zhou A, Williams BR, Silverman RH (1998) Identification of genes
differentially regulated by interferon alpha, beta, or gamma using oligonucle-
otide arrays. Proc Natl Acad Sci U S A 95: 15623–15628.
35. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, et al. (2001)
Identification of CpG oligonucleotide sequences with high induction of IFN-
alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 31: 2154–2163.
36. Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, et al. (1997) Coreceptor
usage of primary human immunodeficiency virus type 1 isolates varies according
to biological phenotype. J Virol 71: 7478–7487.
37. Moir S, Lapointe R, Malaspina A, Ostrowski M, Cole CE, et al. (1999) CD40-
Mediated induction of CD4 and CXCR4 on B lymphocytes correlates with
restricted susceptibility to human immunodeficiency virus type 1 infection:
potential role of B lymphocytes as a viral reservoir. J Virol 73: 7972–7980.
38. Chun TW, Engel D, Berrey MM, Shea T, Corey L, et al. (1998) Early
establishment of a pool of latently infected, resting CD4(+) T cells during
primary HIV-1 infection. Proc Natl Acad Sci U S A 95: 8869–8873.
39. Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of
normalization methods for high density oligonucleotide array data based on
variance and bias. Bioinformatics 19: 185–193.
40. Matthews TJ, Weinhold KJ, Lyerly HK, Langlois AJ, Wigzell H, et al. (1987)
Interaction between the human T-cell lymphotropic virus type IIIB envelope
glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in
binding and cell fusion. Proc Natl Acad Sci U S A 84: 5424–5428.
Plasmacytoid DCs Suppress HIV
PLoS ONE | www.plosone.org 10 2007 | Issue 5 | e458